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In order to obtain information on a possible causative connection between the excretion of certain tryptophane metabolites and the
etiology of cancer of the urinary bladder and to evaluate the influence of smoking on the etiology of this malignant disease, the following
groups were formed:
I. Healthy persons, smokers, . healthy persons, non-smokers, III. patients (no bladder cancer), smokers, IV. patients (no bladder cancer)
non-smokers, V. patients with bladder cancer, smokers. The following tryptophane metabolites were estimated: Kynurenine, 3-hydroxy-
kynurenine, 3-hydroxy-anthranilic acid, N'-methyl-nicotinamide.
No significant differences between the study groups could be found by the analysis of variance. However, there was some indication for
a larger variation in the group of cancer patients.
Um die Möglichkeit des kausativen Zusammenhanges zwischen der Ausscheidung von bestimmten Tryptophanmetaboliten und der
Ätiologie des Harnblasencarcinoms und den Einfluß des Rauchens auf die Entstehung dieser malignen Tumoren zu prüfen, wurden die
folgenden Versuchsgruppen gebildet :
I. Gesunde Probanden, Raucher, II. gesunde Probanden, Nichtraucher, III. Patienten (kein Blasen-Carcinom), Raucher, IV. Patienten
(kein Blasen-Carcinom), Nichtraucher, V. Patienten mit Blasen-Carcinom, Raucher. Die Konzentrationen der folgenden Metabolite im
24-h-Harn wurden bestimmt: Kynurenin, 3-Hydroxykynurenin, 3-Hydroxyanthranilsäure, N'-Methylnicotinamid.
Es konnte mit der Varianzanalyse keine signifikanten Unterschiede zwischen den Gruppen nachgewiesen werden; jedoch deuten weitere
statistische Analysen an, daß die Gruppe der Krebspatienten durch eine größere Variabilität gekennzeichnet ist.
An impressive example for environmental carcino- time, an hypothesis about the endogenous mechanism
genesis, which has been known for a long time, is cancer of a cancer etiology was proved experimentally. It is
of the urinary bladder. Certain carcinogenic aromatic thus astonishing, that only relatively few investigations
amines have proved to be the cause of industrial bladder exist on this subject (4). We think that the lack of
cancer. In the course of investigations which were based relevant investigations is due to analytical difficulties.
on theoretical conceptions endogenous compounds In retrospective and prospective studies, an epidemio-
have also been found to be able to produce bladder logical and statistical connection between the occurrence
cancer in mice after local application (BOYLAND (1)). of bkdder cancer and smoking of cigarettes (review see
Furthermore BOYLAND et al. found, that patients with by (5)) has been found. In 1965 KERR et al. (6) reported
urinary bladder cancer excrete more carcinogenic endo- on the impairment of tryptophane metabolism by
genous substances than normal persons. These facts smoking. They measured the excretion of tryptophane
represented a coincidence of experimental and clinical metabolites in six subjects before and after smoking and
findings in cancer research. For the first time, the found that after tryptophane loading, the test persons
enhanced production of an endogenous compound had excreted more 3-hydroxy-kynurenine and more 3-
been recognized as a carcinogenic agent. The compounds hydroxy-anthranilic acid during a smoking period than
which proved to be carcinogenic, are 3-hydroxy-kynure- during abstinence from smoking.
nine, 3-hydroxy-anthranilic acid, and 2-amino-3-hy- This was in fact a remarkable finding, which proved for
droxy-acetophenone. the first time a metabolic block in a natural degradation
The finding of BOYLAND et al. (2, 3) that the activity of mechanism caused by tobacco smoke constituents.
esterases, which split the conjugated forms of the above ______
mentioned compounds is elevated in the urine of pa-
tients with bladder cancer, provided additional evidence !> ™ °f "* p,ap" ?" * " ? *" 2°°**^ ° t°
, , . ' * , . . . "Deutsche Gesellschaft für Klinische Chemie and "Deutsche
for the concept of impaired tryptophane metabolism as Gesellschaft für Hämatologie", 27"> and 28* September 1972 in
a cause of urinary bladder cancer in man. For the first Höhenried.
•
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These findings are of great importance from the bio-
chemical as well as from the etiological point of view.
A confirmation of these findings can give additional
evidence for the etiological significance of .endogenous
compounds in urinary bladder cancer. In earlier in-
vestigations we found that cigarette smoke is able to
influence tryptophane metabolism (7, 8). We could
show that cigarette smoke inhibits kynureninase in
vitro, but activates this enzyme in the liver of hamsters
exposed to cigarette smoke. The activity of tryptophane
pyrrolase is inhibited in vitro and in vivo by application
of cigarette smoke.
In light of these preliminary considerations and experi-
mental findings, we decided to reinvestigate with im-
proved methods the excretion of carcinogenic trypto-
phane metabolites in normal persons and in patients with
urinary bladder cancer. We were especially interested in
any correlations with smoking habits.
We have already mentioned the suspicion that the lack
of reliable clinical-chemical methods for the measure-
ment of the carcinogenic compounds in question has
been the cause for the lack of confirming or non-
confirming studies on this subject. During preliminary
studies on .suitable chemical methods we found that
several methods which are described in the literature,
and which were used earlier by other investigators,
did not fullfill the requirements of modern analytical
methods with respect to precision and specificity. We
directed our attention to the estimation of the carcino-
genic compounds 3-hydroxy-kynurenine and 3-hydroxy-
anthranilic acid. After having found that none of the
methods described in the literature were sufficient for
our investigations, we developed a combined enzymatic
method for the estimation of 3-hydroxy-kynurenine and
3-hydroxy-anthranilic acid in urine which is extremely
specific (9).
The findings which we will present in this paper are
very different from the above mentioned findings of
other authors. Therefore, we will give a detailed de-
scription of materials and methods used.
Materials and Methods
The tryptophane metabolism is dependent on. the diet, and as we
were looking for possible differences with regard to smoking
habits, the need arose to form the following groups:
1. Normal persons, smokers
2. Normal persons, non-smokers
3. Patients without bladder cancer, smokers
4. Patients without bladder cancer, non-smokers
5. Patients with bkdder cancer, smokers.
• ι
For the purpose of this investigation, smokers were defined as
smokers if they smoked regularly or did so during a time period
in their life regardless of their present smoking habits. Non-
smokers had never smoked regularly in their lives.
Normal persons were volunteers from the hospital staff or persons
known to the hospital staff. Patients with bladder cancer were
inmates of the urological clinic of the University Of Munich, and
patients without bladder cancer were inmates of the same hospital.
Most of them suffered from bone fractures but they were on the
same diet as the bladder cancer patients. Table 1 summarizes sex
and age distribution and smoking habits for the 5 study groups.
The original number of persons in groups 3 to 5 was considerably
greater, but for reasons which will be mentioned later, a sub-
stantial number of the urine specimens could not be analysed
because of the lack of stability of 3-hydroxy-anthranilic acid (for
details see "chemical methods"). Group 3 and 4 consisted mostly
of patients with bone fractures. They were inmates in the same
University hospital as the patients of group 5 and received the
same diet. Group 5 consisted only of patients with bladder cancer
which had been histologically verified in the excised tumor.
Histological examinations were performed in the Institute of
Pathology, University of Munich.
During the time of this study, we had only two patients with
bladder cancer who were non-smokers. The values found in
these patients are not included in this study because such a small
number would not give reliable results.
Urine was collected during 24 h before surgical treatment. To
the first urine portion, 5 ml concentrated HC1 (D = 1.19) was
added. All urine samples which were more alkaline than pH 6
were discarded for reasons which will be mentioned later. Immedi--
ately after collection, each urine sample was portioned into
separate containers for the different chemical estimations and
kept frozen until used.
Chemical methods
The following tryptophane metabolites were measured: kynure-
nine, 3-hydroxy-anthranilic acid, 3-hydroxy-kynurenine, and
N'-methyl-nicotinamide. 3-Hydroxy-kynurenine and 3-hydroxy-
Tab. I
Age and sex distribution and smoking of the study groups
Study group nr.
1 smokers
Normal persons
2 non-smokers
3 smokers*
Patients without bladder cancer
4 non-smokers
Patients with bladder cancer 5 smokers
Sex
c?
9
0"
9
tf
9
cf
9
d1
9
n
9
13
7
6
18
5
3
19
14
4
Age
(range)
28—50
26—49
26—34
23—59
28—72
26—54
45—69
50—71
40—71
45—70
Cigarettes consumed*
Daily Years
(mean)
10
•jo£0
g
onΛΛ)
IQlo
* In group 1 one person smoked cigars and four smoked pipes in addition.
In group 3 two patients smoked cigars and pipes in addition to cigarettes.
In group 5 one patient smoked pipe, two patients smoked cigars and one patient smoked pipes and cigars.
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anthranilic acid were estimated in the free and in the conjugated
form.
Kynurenine
This metabolite was evaluated by the method of TOMPSETT (10).
The method is based upon alkaline distillation of the urine and
the consequent forming of o-amino acetophenone. This compound
is measured in the distillate by a diazo reaction. In the original
method, the distillate is collected in three test tubes. Normally,
the third tube shows only traces of colored material after the
reaction. In several urine samples, we found an extremely high
content of diazo positive material which was still present in the
fifth or sixth test tube. Thin-layer chromatography and other
methods showed that this material was not all kynurenine. Con-
sequently, the values obtained from these urines which had been
collected from persons of all groups, were not included into the
interpretation of this study.
3-Hydroxy-kynurenine and 3-Hydroxy-anthranilic
acid
At first we tried to estimate both of these substances by column
and thin layer chromatography. A satisfactory separation between
kynurenine and 3-hydroxy-kynurenine could not be obtained by
these methods. Therefore, we developed an enzymatic method,
which is based upon the conversion of 3-hydroxy-kynurcnine
and 3-hydroxy-anthranilic acid by kynureninase (L-kynurenine-
hydrolase, EC 3.7.1.3) and 3-hydroxy-anthranilic acid oxidase
(3-hydroxy-anthranilate: O2 oxidoreductase, EC 1.13.1.6), re-
spectively into a degradation product which can be measured at
340 nm. The amount of the product is equivalent to the amount
of 3-hydroxy-kynurenine and 3-hydroxy-anthranilic acid present
in the urine (9). This method is absolutely specific for the two
mentioned compounds. 3-Hydroxy-anthranilic acid is a very labile
compound and can decompose easily in solutions with a pH
higher than 6 (11), so no urine samples which were more alkaline
than 6 were used for the estimation of 3-hydroxy-anthranilic acid.
For hydrolysis of the conjugated compounds, a mixture of ß-
glucuronidase and arylsulfatase (Boehringer Mannheim) was
used.
N'-methylnicotinamide was estimated by the method des-
cribed by CARPENTER and KODICEK (12).
Biostatistics
As the data contain some gross outliers, the study groups will
be characterized by the median instead of the more usual arith-
metic mean.
The testing for group differences presents some difficulties with
regard to the multitude of hypotheses to be tested: as is well-
known an increased number of tests will lead to an increased
number of wrong statements. For this reason it was decided to
analyse the data by means of an analysis of variance (ANOVA).
This helps to keep the overall error for the comparison of the
five study groups within certain prespecified bounds, for which
we choose the conventional 5%-level. As we were very concerned
about not overlooking a real difference (/5-error) we decided to
admit an = 0.05 for each of the seven variables.
The analyses of variance were performed with the help of a
linear model whose fit could be tested by inspection of the so
called residual plots.
Some of the distributions were analysed graphically by plotting
them into probability paper. The handling of small samples by
this technique has been described in detail by L. G. JOHNSON (13).
Results
The median values2) for the different study groups con-
cerning the tryptophane metabolites are presented in
Table 2 and 3. Group comparisons for each variable
with respect to the mean were performed by the overall
F-test of an analysis of variance (one way analysis).
Inspection of the residuals in normal probability paper
revealed that the data situation could be improved by a
logarithmic transformation of all data (X = logjo
(X + 1)). After transformation the residuals showed
a sufficiently normal distribution although in some cases
the extreme ends left something to be desired.
2) The median is an alternative measure for the central tendency
of a distribution. It is defined as that point on the scale of ob-
servations on each side of which are equal areas under the histo-
gram (the 50th percentile). Thus the median is the middle ob-
servation if there is an odd number of cases.
Tab. 2
Excretion of 3-hydroxy-kynurenine and S^hydroxy-anthranilic acid in free and conjugated form in the urine. Median values, mg/24 h
n = number of persons in the group, n+ = number of assays
Group 3-hydroxy-kynurenine
free n+ total
3-hydroxy-anthranilic acid
free n+ total
1
2
3
4
5
22
13
23
22
18
0.41
0.44
0.79
0.33
0.76
21
13
20
20
14
0.52
0.50
1.29
0.48
1.14
21
13
20
20
13
0.32
0.23
0.33
0.22
0.36
22
13
20
21
16
0.56
0.39
0.51
0.33
0.56
22
13
20
21
14
Tab. 3
Excretion of N'-methyl-nicotinamide, kynurenine and creatinine. Median values
n «s number of persons in the group, n+ = number of assays
Group
1
2
3
4
5 ··"·
n
22
13
23
22
18
N'-methyl-
nicotinamide
mg/24 h
3.26
3.38
1.79
2.78
1.99
n+
22
13
22
22
18
Kynurenine
mg/24 h
1.32
1.23
1.81
2.42
8.86
n+
21
13
22
16
13
Creatinine
g/24 h
1.50
1.43
1.76
1.39
0.99
n+
22
13
23
22
18
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In none of the five analyses was there a significant F-
value, although some single t-test comparisons reach the
level of significance.
The compounds 3-hydroxy-kynurenine and 3-hydroxy-
anthranilic acid in the free form were analysed in
more detail. The groups of cancer patients and
smokers from hospital are contrasted in probability
paper with logarithmic abscissa (Fig. 1 and 2) as
well as the two healthy groups of smokers and non-
smokers (Fig. 3 and 4).
It may be derived from Figure 1 that there is some indi-
cation for a different distribution of the measurements
for the two groups: there is more variation in the group
of cancer patients. The difference of the two distributions
with respect to their variability, however, could not be
shown to be statistically significant (SIEGEL and TUKEY
test; p > 0.10). The graphical representation of the cases
suggest that the different study groups in themselves
are very inhomogeneous*
As for normal persons, smokers and non smokers do not
differ substantially (Fig. 3 and 4). There is practically no
difference with respect to 3-hydroxy-anthranilic acid in
patients (Fig. 2). The representation, of normal patients
suggests that there might be a difference between
smokers and non-smokers with respect to the central
tendency of the distribution (Fig. 3). The difference,
however, might still be explained by chance alone
(WiLCOXON rang sum test).
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Fig. 1
Excretion of free 3-hydroxy-kynurenine in study groups 3 and 5( χ = patients without bladder cancer, smokers, ο = cancer patients,
smokers) on probability paper
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Excretion of free 3-hydroxy-anthranilic acid in study groups 3 and 5(x = patients without bladder cancer, smokers, ο = patients with
bladder cancer, smokers) on probability paper
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Diskussion
The analyses of variance resulted in the verdict of "no
significant differences" which — as one should bear in
mind — does not imply that there is' none. There is
much variation in the data which may camouflage real
differences. And of course the F-test is less sensitive if the
number of groups increases. We adhered to the F-test,
however, because we prefer a more conservative decision
concerning the null-hypothesis of no group difference.
It may be noted that there exists a high degree of non-
homogeneity in most distributions as was displayed by
the graphic representation of the data. For the 3-hy-
droxy-kynurenine variable there is some indication that
the group of cancer patients shows a greater variabi-
lity than the comparable study group of smoking
patients.
The findings of BOYLAND et al. (1, 2, 3) and of several
other investigators show that patients with bladder
cancer excrete more carcinogenic tryptophane metabolites
than do normal persons. Our results do not confirm
these earlier results. The difference between our findings
and those of the above mentioned authors may be based
upon the different methods used for the estimation of the
tryptophane metabolites. TOMPSETT (10) already ob-
served that the urine of patients with malignant disease
of the bladder sometimes contains nbn specific dia-
20table volatile amines in appreciable amounts. This
confirms our findings with regard to the results of
kynurenine estimations mentioned earlier.
The methods used by us for the estimation of 3-hydroxy-
kynurenine and 3-hydroxy-anthranilic acid are absolutely
specific. They can be controlled by running a control
sample of the respective urine with standard substance.
In this way an inhibitor or other disturbing substances
present in the urine, which may interfer with the assay
can be detected.
Our investigations did not produce any indication that
a correlation exists between the excretion of certain
tryptophane metabolites and the etiology of bladder
cancer. In earlier investigations we could show that
cigarette smoke may interfere with tryptophane meta-
bolism in vivo and in vitro (7, 8), but the present findings
do not show any significant correlation between cigarette
smoking and bladder cancer. Our findings are contrary
the the results of KERR et al. (6). This group of authors
found a positive correlation between cigarette smoking
and excretion of certain tryptophane metabolites. They
used the methods criticized above, and moreover, they
had only six persons in their study and measured the
metabolites after tryptophane loading.
Our results are in accordance with results of BROWN
et al. (14) and of ALPEROVITCH (15), who also could not
confirm the results of KERR et al. (6). Moreover, we
think that measurement of tryptophane metabolism after
tryptophane loading may not reflect the true conditions.
But in the past, this has been necessary as no methods
existed which were sensitive enough to measure the
normal excretion.
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